Scott M. Lippman

63.6k total citations · 11 hit papers
528 papers, 37.2k citations indexed

About

Scott M. Lippman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Scott M. Lippman has authored 528 papers receiving a total of 37.2k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Oncology, 183 papers in Molecular Biology and 142 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott M. Lippman's work include Lung Cancer Treatments and Mutations (77 papers), Retinoids in leukemia and cellular processes (76 papers) and Head and Neck Cancer Studies (62 papers). Scott M. Lippman is often cited by papers focused on Lung Cancer Treatments and Mutations (77 papers), Retinoids in leukemia and cellular processes (76 papers) and Head and Neck Cancer Studies (62 papers). Scott M. Lippman collaborates with scholars based in United States, Japan and Australia. Scott M. Lippman's co-authors include Waun Ki Hong, John V. Heymach, J. Jack Lee, Roy S. Herbst, Adel K. El‐Naggar, Everett E. Vokes, Ian M. Thompson, Ralph R. Weichselbaum, Phyllis J. Goodman and Charles A. Coltman and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Scott M. Lippman

523 papers receiving 36.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung Cancer

2008 2.0k citations Scott M. Lippman et al. profile →
Head and Neck Cancer

1993 1.8k citations Scott M. Lippman, Waun Ki Hong et al. profile →
The Influence of Finasteride on the Development of Prostate Cancer

2003 1.7k citations Scott M. Lippman et al. profile →
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Scott M. Lippman et al. profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Edward S. Kim, Scott M. Lippman et al. profile →
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

2012 766 citations Scott M. Lippman, Adel K. El‐Naggar et al. profile →
Statins and cancer prevention

2005 647 citations Ernest T. Hawk, Scott M. Lippman et al. profile →
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

2019 429 citations Jason K. Sicklick, Shumei Kato et al. profile →
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence

2017 425 citations Scott M. Lippman et al. profile →
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)

2010 388 citations Scott M. Lippman et al. profile →
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

2021 174 citations Alfredo Molinolo, Scott M. Lippman et al. profile →

Peers

Countries citing papers authored by Scott M. Lippman

Since Specialization

Citations

This map shows the geographic impact of Scott M. Lippman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott M. Lippman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott M. Lippman more than expected).

Fields of papers citing papers by Scott M. Lippman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott M. Lippman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott M. Lippman. The network helps show where Scott M. Lippman may publish in the future.

Co-authorship network of co-authors of Scott M. Lippman

This figure shows the co-authorship network connecting the top 25 collaborators of Scott M. Lippman. A scholar is included among the top collaborators of Scott M. Lippman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott M. Lippman. Scott M. Lippman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer 2019 ·Cancer Research ·(unknown), Ajaz Bulbul, John Paul Shen, (unknown), Brian Woodward, Fernando J. López-Díaz, Scott M. Lippman, Hatim Husain	164
2	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma 2018 ·Clinical Cancer Research ·Shumei Kato, Ryosuke Okamura, Joel Baumgartner, Hitendra Patel, Lawrence Leichman, Kaitlyn J. Kelly, Jason K. Sicklick, Paul T. Fanta, Scott M. Lippman, Razelle Kurzrock	94
3	The Ashitaba ( Angelica keiskei ) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K 2018 ·Cancer Prevention Research ·Tianshun Zhang, Qiushi Wang, (unknown), Ge Gao, Keke Wang, Hanyong Chen, Ting Wang, Naomi Oi, Tatyana A. Zykova, Kanamata Reddy, Ke Yao, Weiya Ma, (unknown), Mee‐Hyun Lee, Moeez Rathore, Ann M. Bode, Hitoshi Ashida, Scott M. Lippman, Zigang Dong	11
4	Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial 2018 ·Clinical Cancer Research ·Terry A. Day, Keisuke Shirai, Paul E. O’Brien, Maria Gisele Matheus, (unknown), Amit J. Sood, Anvesh Kompelli, (unknown), Daniel Martı́n, Lynn Vitale‐Cross, (unknown), Zhiyong Wang, Xingyu Wu, Olivier Harismendy, Alfredo Molinolo, Scott M. Lippman, Carter Van Waes, Éva Szabó, J. Silvio Gutkind	67
5	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary 2017 ·Cancer Research ·Shumei Kato, Nithya Krishnamurthy, Kimberly C. Banks, Pradip De, Kirstin Williams, Casey Williams, Brian Leyland‐Jones, Scott M. Lippman, Richard B. Lanman, Razelle Kurzrock	90
6	Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer 2017 ·Cancer Discovery ·Hannah Carter, Rachel Marty, Matan Hofree, Andrew M. Gross, James Jensen, Kathleen M. Fisch, Xingyu Wu, Christopher DeBoever, Eric L. Van Nostrand, Yan Song, Emily C. Wheeler, Jason F. Kreisberg, Scott M. Lippman, G Yeo, J. Silvio Gutkind, Trey Ideker	87
7	Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew Stephens, Ronit Simantov, Srinivasu Poondru, (unknown), Scott M. Lippman, Stan B. Kaye, Craig P. Carden	77
8	Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications 2014 ·Clinical Cancer Research ·Yoshitsugu Mitani, Pulivarthi H. Rao, Sankar N. Maity, Yu-Chen Lee, Renata Ferrarotto, (unknown), Lisa Licitra, Scott M. Lippman, Merrill S. Kies, Randal S. Weber, Carlos Caulı́n, Sue-Hwa Lin, Adel K. El‐Naggar	56
9	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer 2012 ·Cancer Prevention Research ·Katherine D. Crew, Powel H. Brown, Heather Greenlee, Therese B. Bevers, Banu Arun, Clifford A. Hudis, Heather L. McArthur, Jenny C. Chang, Mothaffar F. Rimawi, Lana A. Vornik, Terri L. Cornelison, Antai Wang, Hanina Hibshoosh, Aqeel Ahmed, Mary Beth Terry, Regina M. Santella, Scott M. Lippman, Dawn L. Hershman	76
10	Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study 2012 ·Clinical Cancer Research ·Pu Xia, Yuanqing Ye, Margaret R. Spitz, Liang Wang, Jian Gu, Scott M. Lippman, Michelle A.T. Hildebrandt, Waun Ki Hong, John D. Minna, Jack A. Roth, Ping Yang, Xifeng Wu	11
11	Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB – NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome 2011 ·Clinical Cancer Research ·Yoshitsugu Mitani, Pulivarthi H. Rao, P. Andrew Futreal, Dianna Roberts, Philip J. Stephens, Yi-Jue Zhao, Li Zhang, (unknown), Randal S. Weber, Scott M. Lippman, Carlos Caulı́n, Adel K. El‐Naggar	116
12	Profiling Lipoxygenase Metabolism in Specific Steps of Colorectal Tumorigenesis 2010 ·Cancer Prevention Research ·Imad Shureiqi, Dongning Chen, R. Sue Day, Xiangsheng Zuo, (unknown), William A. Ross, Rhonda A. Cole, (unknown), Jeffrey S. Morris, Lianchun Xiao, Robert A. Newman, Peiying Yang, Scott M. Lippman	46
13	Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance 2010 ·Clinical Cancer Research ·Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-Jue Zhao, Diana Bell, Scott M. Lippman, Randal S. Weber, Carlos Caulı́n, Adel K. El‐Naggar	219
14	Cancer Prevention: From 1727 to Milestones of the Past 100 Years 2009 ·Cancer Research ·Scott M. Lippman, Ernest T. Hawk	97
15	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells 2009 ·Molecular Cancer Therapeutics ·Ralph Zinner, (unknown), Elmira Popova, Paul Damien, Andrei Y. Volgin, Juri G. Gelovani, Reuben Lotan, Hai T. Tran, Claudio Pisano, Gordon B. Mills, (unknown), Waun Ki Hong, Scott M. Lippman, John H. Miller	48
16	High-Dose Fenretinide in Oral Leukoplakia 2009 ·Cancer Prevention Research ·William N. William, J. Jack Lee, Scott M. Lippman, Jack W. Martin, Nitin Chakravarti, Hai T. Tran, Anita L. Sabichi, Edward S. Kim, Lei Feng, Reuben Lotan, Vassiliki A. Papadimitrakopoulou	33
17	Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development 2009 ·Cancer Research ·Woo-Young Kim, Quanri Jin, (unknown), Edward S. Kim, (unknown), Dong Hoon Lee, Lei Feng, Carmen Behrens, Ludmila Prudkin, York E. Miller, J. Jack Lee, Scott M. Lippman, Waun Ki Hong, Ignacio I. Wistuba, Ho‐Young Lee	60
18	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial 2009 ·Journal of Clinical Oncology ·Merrill S. Kies, Floyd Christopher Holsinger, J. Jack Lee, William N. William, Bonnie S. Glisson, Heather Lin, Jan S. Lewin, Lawrence E. Ginsberg, (unknown), Erminia Massarelli, Lauren A. Byers, Scott M. Lippman, Waun Ki Hong, Adel K. El‐Naggar, Adam S. Garden, Vassiliki A. Papadimitrakopoulou	187
19	Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients 2009 ·Cancer Prevention Research ·Vassiliki A. Papadimitrakopoulou, Julie Izzo, Diane D. Liu, Jeffrey N. Myers, (unknown), Jan S. Lewin, William N. William, (unknown), J. Jack Lee, Ann M. Gillenwater, Adel K. El‐Naggar, Xifeng Wu, Scott M. Lippman, Walter N. Hittelman, Waun Ki Hong	32
20	Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non–Small Cell Lung Cancer 2008 ·Cancer Research ·Hye‐Sook Seo, Diane D. Liu, B. Nebiyou Bekele, Mi-Kyoung Kim, Katherine M.W. Pisters, Scott M. Lippman, Ignacio I. Wistuba, Ja Seok Koo	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact